Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis
Burgos-Vargas, R.én.; Rojas-Serrano, J.
Journal of Rheumatology 32(9): 1637-1640
2005
ISSN/ISBN: 0315-162X PMID: 16142852 Document Number: 585639
Document emailed within 1 workday
Related Documents
Appel, H.; Scheer, R.; Haibel, H.; Wu, P.; Spiller, I.; Brandt, H.; Song, I-Ho.; Rudwaleit, M.; Thiel, A.; Sieper, J. 2007: In vitro observations of T cell responsiveness to recall antigens during tumor necrosis factor-alpha-blocking therapy in patients with ankylosing spondylitis Journal of Rheumatology 34(11): 2264-2270Zochling, J.; Sieper, J.; van der Heijde, Désirée.; Braun, Jürgen.; Weber, U.; Rudwaleit, M.; Leirisalo-Repo, M.; Collantes-Estévez, E.; van der Horst-Bruinsma, I.; Géher, P.; Kvien, T.; deVlam, K.; l Ostergaard, M.; Maksymowych, W. 2008: Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy Journal of Rheumatology 35(6): 1079-1082
Kaneko, H.; Yamada, H.; Mizuno, S.; Udagawa, T.; Kazumi, Y.; Sekikawa, K.; Sugawara, I. 1999: Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice Laboratory Investigation; a Journal of Technical Methods and Pathology 79(4): 379-386
Broudy, V.C.; Harlan, J.M.; Adamson, J.W. 1987: Disparate effects of tumor necrosis factor-alpha/cachectin and tumor necrosis factor-beta/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells Journal of Immunology 138(12): 4298-4302
Alsalameh, S.; Mattka, B.; Al-Ward, R.; Lorenz, H.M.; Manger, B.; Pfizenmaier, K.; Grell, M.; Kalden, J.R. 1999: Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor Journal of Rheumatology 26(3): 645-653
Brach, M.A.; Herrmann, F. 1993: The mitogenic response of AML blasts to tumor necrosis factor-alpha requires functional c-jun/AP-1 Leukemia 7(Suppl): S22-S26
Bebök, Z.; Szekeres, G.; Horváth, G.; Duda, E.; Németh, P. 1993: Creation of monoclonal antibodies against tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor alpha (TFG-alpha), their definition and possible use Orvosi Hetilap 134(24): 1303-1307
Manni, L.; Lundeberg, T.; Fiorito, S.; Bonini, S.; Vigneti, E.; Aloe, L. 2003: Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response Clinical and Experimental Rheumatology 21(5): 617-624
Daniel, L.W.; Civoli, F.; Rogers, M.A.; Smitherman, P.K.; Raju, P.A.; Roederer, M. 1995: ET-18-OCH3 inhibits nuclear factor-kappa B activation by 12-O-tetradecanoylphorbol-13-acetate but not by tumor necrosis factor-alpha or interleukin 1 alpha Cancer Research 55(21): 4844-4849
Tanaka, N.; Kojima, K.; Muro, M.; Naomoto, Y.; Moreira, L.F.; Orita, K. 1995: Anti-proliferative and cytokinetic effects of tumor necrosis factor-alpha, interferon-alpha and 5-fluorouracil on a human tumor xenograft Anticancer Research 15(5b): 1949-1952
Pachot, A.; Arnaud, Béatrice.; Marrote, H.; Cazalis, M-Angélique.; Diasparra, J.; Gouraud, A.; Mougin, B.; Miossec, P. 2007: Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response Journal of Rheumatology 34(11): 2158-2161
Grazio, S.; Grubisić, F.; Nemcić, T.; Matijević, V.; Skala, H. 2009: The reliability and validity of a Croatian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis Reumatizam 56(2): 63-76
Keane, J.; Ní Cheallaigh, C. 2008: Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge Journal of Rheumatology 35(7): 1238-1239
Savastano, M.; Marioni, G.; Giacomelli, L.; Ramonda, R.; Ferraro, S.M.; Punzi, L. 2010: Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers B-Ent 6(3): 183-188
Wang, Q.; Wu, X.; Wang, J.; Liu, H.; Li, L.; Jin, X. 2005: Building immune microsphere against tumor necrosis factor-alpha (TNF-alpha) Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 22(6): 1219-1222
Zaremba, J.; Losy, J. 2001: Tumor necrosis factor alpha (TNF-alpha) in patients with ischemic stroke Neurologia i Neurochirurgia Polska 35(1): 41-46
Serwin, A.B.; Flisiak, I.; Chodynicka, B. 2004: The role of tumor necrosis factor alpha receptors (TNF-alpha) in psoriasis and other skin disorders Wiadomosci Lekarskie 57(11-12): 686-690
Tsuji, Y.; Ninomiya-Tsuji, J.; Torti, S.V.; Torti, F.M. 1993: Augmentation by IL-1 alpha of tumor necrosis factor-alpha cytotoxicity in cells transfected with adenovirus E1A Journal of Immunology 150(5): 1897-1907
Belaiche, J.; Louis, E. 2000: Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies Revue Medicale de Liege 55(9): 827-832
Xie, W.; Sun, J.; Zhang, X.; Melzig, M.F. 2014: Necrosis factor-alpha (TNF-alpha) response in human hepatoma HepG2 cells treated with hepatotoxic agents Die Pharmazie 69(5): 379-384